CCNU (Lomustine) - Revision history

Lazy at 08:21, 18 January 2025

2025-01-18T08:21:49Z

← Older revision		Revision as of 01:21, 18 January 2025
Line 28:		Line 28:
	standard therapy for newly diagnosed glioblastoma is currently being tested in a phase 3		standard therapy for newly diagnosed glioblastoma is currently being tested in a phase 3
	trial in Germany.		trial in Germany.
	}}		\|overview=CCNU (Lomustine) is an FDA-approved chemotherapy drug used for treating glioblastoma, demonstrating a median survival of 23 months with a 47% two-year survival rate; however, it is associated with significant side effects, including hematological toxicity, nausea, and pulmonary toxicity, which contribute to its high toxicity level rating of 4. A clinical trial in Germany has shown promising results, particularly in patients with methylated MGMT, indicating potential benefit when used in combination with TMZ.}}

Lazy at 16:25, 30 December 2024

2024-12-30T16:25:28Z

← Older revision		Revision as of 09:25, 30 December 2024
Line 8:		Line 8:
	\|usefulness_rating=4		\|usefulness_rating=4
	\|notes=A combination of TMZ with CCNU showed promising results including a 5-year survival rate of 16% among a small patient cohort. MGMT methylation status significantly influenced outcomes.		\|notes=A combination of TMZ with CCNU showed promising results including a 5-year survival rate of 16% among a small patient cohort. MGMT methylation status significantly influenced outcomes.
	\|treatment_category=~~Other~~ Chemotherapy ~~and Cancer Drugs~~		\|treatment_category=SOC Chemotherapy
	\|toxicity_level=4		\|toxicity_level=4
	\|toxicity_explanation=The toxicity level of CCNU is quite high due to several common side effects. Most notably, it can cause hematological toxicity, which means it can damage your blood cells and affect your body's ability to fight infections and clot properly. It can also cause nausea, vomiting, and pulmonary toxicity, which can lead to lung damage. On a scale from 1 to 5, with 5 being the most toxic, CCNU is rated as a 4. However, despite these side effects, the treatment showed promising results in a clinical trial.		\|toxicity_explanation=The toxicity level of CCNU is quite high due to several common side effects. Most notably, it can cause hematological toxicity, which means it can damage your blood cells and affect your body's ability to fight infections and clot properly. It can also cause nausea, vomiting, and pulmonary toxicity, which can lead to lung damage. On a scale from 1 to 5, with 5 being the most toxic, CCNU is rated as a 4. However, despite these side effects, the treatment showed promising results in a clinical trial.

69.163.248.232: Updated category= to treatment_category= in TreatmentInfo template

2024-11-12T18:33:15Z

Updated category= to treatment_category= in TreatmentInfo template

← Older revision		Revision as of 11:33, 12 November 2024
Line 8:		Line 8:
	\|usefulness_rating=4		\|usefulness_rating=4
	\|notes=A combination of TMZ with CCNU showed promising results including a 5-year survival rate of 16% among a small patient cohort. MGMT methylation status significantly influenced outcomes.		\|notes=A combination of TMZ with CCNU showed promising results including a 5-year survival rate of 16% among a small patient cohort. MGMT methylation status significantly influenced outcomes.
	\|~~category~~=Other Chemotherapy and Cancer Drugs		\|treatment_category=Other Chemotherapy and Cancer Drugs
	\|toxicity_level=4		\|toxicity_level=4
	\|toxicity_explanation=The toxicity level of CCNU is quite high due to several common side effects. Most notably, it can cause hematological toxicity, which means it can damage your blood cells and affect your body's ability to fight infections and clot properly. It can also cause nausea, vomiting, and pulmonary toxicity, which can lead to lung damage. On a scale from 1 to 5, with 5 being the most toxic, CCNU is rated as a 4. However, despite these side effects, the treatment showed promising results in a clinical trial.		\|toxicity_explanation=The toxicity level of CCNU is quite high due to several common side effects. Most notably, it can cause hematological toxicity, which means it can damage your blood cells and affect your body's ability to fight infections and clot properly. It can also cause nausea, vomiting, and pulmonary toxicity, which can lead to lung damage. On a scale from 1 to 5, with 5 being the most toxic, CCNU is rated as a 4. However, despite these side effects, the treatment showed promising results in a clinical trial.

Lazy at 04:18, 28 March 2024

2024-03-28T04:18:53Z

@@ Line 11: / Line 11: @@
 |toxicity_level=4
 |toxicity_explanation=The toxicity level of CCNU is quite high due to several common side effects. Most notably, it can cause hematological toxicity, which means it can damage your blood cells and affect your body's ability to fight infections and clot properly. It can also cause nausea, vomiting, and pulmonary toxicity, which can lead to lung damage. On a scale from 1 to 5, with 5 being the most toxic, CCNU is rated as a 4. However, despite these side effects, the treatment showed promising results in a clinical trial.
 }}

Lazy at 16:55, 27 March 2024

2024-03-27T16:55:36Z

← Older revision		Revision as of 09:55, 27 March 2024
Line 9:		Line 9:
	\|notes=A combination of TMZ with CCNU showed promising results including a 5-year survival rate of 16% among a small patient cohort. MGMT methylation status significantly influenced outcomes.		\|notes=A combination of TMZ with CCNU showed promising results including a 5-year survival rate of 16% among a small patient cohort. MGMT methylation status significantly influenced outcomes.
	\|category=Other Chemotherapy and Cancer Drugs		\|category=Other Chemotherapy and Cancer Drugs
			\|toxicity_level=4
			\|toxicity_explanation=The toxicity level of CCNU is quite high due to several common side effects. Most notably, it can cause hematological toxicity, which means it can damage your blood cells and affect your body's ability to fight infections and clot properly. It can also cause nausea, vomiting, and pulmonary toxicity, which can lead to lung damage. On a scale from 1 to 5, with 5 being the most toxic, CCNU is rated as a 4. However, despite these side effects, the treatment showed promising results in a clinical trial.
	}}		}}

Lazy: Created page with "{{TreatmentInfo |drug_name=CCNU (Lomustine) |FDA_approval=Yes |used_for=Glioblastoma |clinical_trial_phase=Phase 3 (Germany) |common_side_effects=Hematological toxicity, nausea, vomiting, and pulmonary toxicity |OS_with=23 months median survival, with 47% at 2 years |usefulness_rating=4 |notes=A combination of TMZ with CCNU showed promising results including a 5-year survival rate of 16% among a small patient cohort. MGMT methylation status significantly influenced outco..."

2024-03-24T13:09:35Z

Created page with "{{TreatmentInfo |drug_name=CCNU (Lomustine) |FDA_approval=Yes |used_for=Glioblastoma |clinical_trial_phase=Phase 3 (Germany) |common_side_effects=Hematological toxicity, nausea, vomiting, and pulmonary toxicity |OS_with=23 months median survival, with 47% at 2 years |usefulness_rating=4 |notes=A combination of TMZ with CCNU showed promising results including a 5-year survival rate of 16% among a small patient cohort. MGMT methylation status significantly influenced outco..."

New page

{{TreatmentInfo
|drug_name=CCNU (Lomustine)
|FDA_approval=Yes
|used_for=Glioblastoma
|clinical_trial_phase=Phase 3 (Germany)
|common_side_effects=Hematological toxicity, nausea, vomiting, and pulmonary toxicity
|OS_with=23 months median survival, with 47% at 2 years
|usefulness_rating=4
|notes=A combination of TMZ with CCNU showed promising results including a 5-year survival rate of 16% among a small patient cohort. MGMT methylation status significantly influenced outcomes.
|category=Other Chemotherapy and Cancer Drugs
}}